Cell and Gene Therapy Bioassay Services Market Fueled by Personalized Medicine Thriving on Innovation

Cell and Gene Therapy Bioassay Services Market worth $ 5.64 Billion by 2030 - Exclusive Report by InsightAce Analytic

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Cell and Gene Therapy Bioassay Services Market- by Type of Therapy (Cell Therapy and Gene Therapy), Therapeutic Area (Oncological, Infectious, Autoimmune, Rare/Genetic, Cardiovascular, Metabolic, Blood, Neurological, Ophthalmic Disorders and Other Therapeutic Areas), Scale of Operation (Discovery, Preclinical and Clinical), Trends, Industry Competition Analysis, Revenue and Forecast To 2030."

Get a free sample copy of the report: https://www.insightaceanalytic.com/request-sample/1208

According to the latest research by InsightAce Analytic, the global Cell and Gene Therapy Bioassay Services Market will be valued at US$ 1.63 Billion in 2021. It is expected to reach US$ 5.64 Billion by 2030, with a CAGR of 15% during a forecast period of 2024-2031.

Cell and Gene Therapies: A Driver for Bioassay Services
Cell and gene therapies are a revolutionary approach to medicine. They involve manipulating a patient's or donor's proteins, cells, or genetic material to create highly targeted and personalized treatments. These therapies hold promise for treating complex and rare diseases and offering longer-lasting benefits compared to conventional options. This has led to a surge in demand for bioassay services specifically designed for gene and cell therapies.

Factors Fueling Market Growth
The growth of the cell and gene therapy bioassay services market is driven by several key factors. Firstly, there is a growing demand for improved medical treatments fueled by an aging population and the rising prevalence of chronic diseases like cancer. Secondly, advancements in genomics technologies are providing researchers with powerful tools to develop new cell and gene therapies.

Thirdly, increasing government investments in research and development (R&D) of novel cell and gene therapies is creating a strong demand for bioassay services to ensure the safety and efficacy of these therapies. Finally, the growing demand for personalized medicine is pushing Contract Research Organizations (CROs) to expand their bioassay service offerings to cater to the development of more efficient and cost-effective gene and cell therapies.

Challenges and Considerations
Despite these promising trends, the market for cell and gene therapy bioassay services faces some potential challenges. The high cost of developing and implementing these therapies could limit market expansion in the coming years. Additionally, a growing number of CROs are entering the market, which could lead to increased competition and potentially impact service pricing.

This revision improves readability by separating the explanation of cell and gene therapies from the market analysis and highlighting the specific factors driving growth and potential challenges.

North America is anticipated to be the major contributor to the Cell and Gene Therapy Bioassay Services Market because of the increasing number of cell and gene therapy product launches and increased R&D activity in biopharma businesses to create cell and gene treatments. In addition, the Asia Pacific regional market is expected to register significant growth because of the high frequency of chronic diseases and genetic abnormalities, the growing older population, patients' increasing need for tailored treatments, and improved technological advances.

Major market players operating in the Cell and Gene Therapy Bioassay Services Market include AnaBioTec (Belgium), CCRM (Canada), Nexelis (Canada), Pacific BioLabs (US), PPD Laboratories (North Carolina), Intertek Pharmaceutical Services (UK), Lonza (Switzerland), Porton Biopharma Ltd (UK), WuXi Advanced Therapies (US), Avomeen (US), Charles River Laboratories (US), Absorption Systems (US), BioAgilytix Labs (US), Catalent, Inc (US), Svar Life Science AB (Sweden), and others.

Recent collaborations and agreements in the market:
• In December 2021, CCRM Enterprises Inc., the company's venture capital arm, purchased Mediphage Bioceuticals, Inc. The investment by CCRM Enterprises will be utilized to fund the development and operation of the technology, as well as access to CCRM's scientific and industrial knowledge. Mediphage is concentrating on developing a non-viral gene therapy platform that will pave the way for individualized genetic treatment that is both safe and effective while also resolving many of the shortcomings of current viral vector-based technologies.

• In April 2021, AavantiBio (US), a gene therapy firm, and Catalent (US), a drug, cell, and gene therapy supplier, collaborated to support the development and manufacture of AavantiBio's gene treatments.

Curious about this latest version of the report? Obtain Report Details @ https://www.insightaceanalytic.com/enquiry-before-buying/1208

Market Segments
Global Cell and Gene Therapy Bioassay Services Market, by Type of Therapy, 2022-2030 (Value US$ Mn)
• Cell Therapy
• Gene Therapy

Global Cell and Gene Therapy Bioassay Services Market, by Therapeutic Area, 2022-2030 (Value US$ Mn)
• Oncological
• Infectious
• Autoimmune
• Rare / Genetic
• Cardiovascular
• Metabolic
• Blood
• Neurological
• Ophthalmic Disorders
• Other Therapeutic Areas

Global Cell and Gene Therapy Bioassay Services Market, by Scale of Operation, 2022-2030 (Value US$ Mn)
• Discovery
• Preclinical
• Clinical

Global Cell and Gene Therapy Bioassay Services Market, by Region, 2022-2030 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

North America Cell and Gene Therapy Bioassay Services Market, by Country, 2022-2030 (Value US$ Mn)
• U.S.
• Canada

Europe Cell and Gene Therapy Bioassay Services Market, by Country, 2022-2030 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe

Asia Pacific Cell and Gene Therapy Bioassay Services Market, by Country, 2022-2030 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand

Latin America Cell and Gene Therapy Bioassay Services Market, by Country, 2022-2030 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa Cell and Gene Therapy Bioassay Services Market, by Country, 2022-2030 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa

Why should buy this report:

 To receive a comprehensive analysis of the prospects for the global Cell and Gene Therapy Bioassay Services Market
 To receive an industry overview and future trends of the Cell and Gene Therapy Bioassay Services Market
 To analyze the Cell and Gene Therapy Bioassay Services Market drivers and challenges
 To get information on the Cell and Gene Therapy Bioassay Services Market value (US$ Mn) forecast to 2030
 Significant investments, mergers & acquisitions in the Cell and Gene Therapy Bioassay Services Market industry

For More Information @ https://www.insightaceanalytic.com/customisation/1208

Contact Us:
InsightAce Analytic Pvt. Ltd.
Tel.: +1 718 593 4405
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions.
Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses.
We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products.
Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

This release was published on openPR.